Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 121

1.

Mepolizumab as a corticosteroid-sparing agent in lymphocytic variant hypereosinophilic syndrome.

Roufosse F, de Lavareille A, Schandené L, Cogan E, Georgelas A, Wagner L, Xi L, Raffeld M, Goldman M, Gleich GJ, Klion A.

J Allergy Clin Immunol. 2010 Oct;126(4):828-835.e3. doi: 10.1016/j.jaci.2010.06.049.

2.

Current strategies in the management of hypereosinophilic syndrome, including mepolizumab.

Schwartz LB, Sheikh J, Singh A.

Curr Med Res Opin. 2010 Aug;26(8):1933-46. doi: 10.1185/03007995.2010.493132. Review.

PMID:
20565230
3.

Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy.

Ogbogu PU, Bochner BS, Butterfield JH, Gleich GJ, Huss-Marp J, Kahn JE, Leiferman KM, Nutman TB, Pfab F, Ring J, Rothenberg ME, Roufosse F, Sajous MH, Sheikh J, Simon D, Simon HU, Stein ML, Wardlaw A, Weller PF, Klion AD.

J Allergy Clin Immunol. 2009 Dec;124(6):1319-25.e3. doi: 10.1016/j.jaci.2009.09.022. Epub .

4.

Treatment of patients with the hypereosinophilic syndrome with mepolizumab.

Rothenberg ME, Klion AD, Roufosse FE, Kahn JE, Weller PF, Simon HU, Schwartz LB, Rosenwasser LJ, Ring J, Griffin EF, Haig AE, Frewer PI, Parkin JM, Gleich GJ; Mepolizumab HES Study Group.

N Engl J Med. 2008 Mar 20;358(12):1215-28. doi: 10.1056/NEJMoa070812. Epub 2008 Mar 16. Erratum in: N Engl J Med. 2008 Jun 5;358(23): 2530.

5.

Long-term safety of mepolizumab for the treatment of hypereosinophilic syndromes.

Roufosse FE, Kahn JE, Gleich GJ, Schwartz LB, Singh AD, Rosenwasser LJ, Denburg JA, Ring J, Rothenberg ME, Sheikh J, Haig AE, Mallett SA, Templeton DN, Ortega HG, Klion AD.

J Allergy Clin Immunol. 2013 Feb;131(2):461-7.e1-5. doi: 10.1016/j.jaci.2012.07.055. Epub 2012 Oct 4.

6.

A review of treatment with mepolizumab, an anti-IL-5 mAb, in hypereosinophilic syndromes and asthma.

Busse WW, Ring J, Huss-Marp J, Kahn JE.

J Allergy Clin Immunol. 2010 Apr;125(4):803-13. doi: 10.1016/j.jaci.2009.11.048. Review.

PMID:
20371394
7.

Eosinophils affect functions of in vitro-activated human CD3-CD4+ T cells.

Harfi I, Schandené L, Dremier S, Roufosse F.

J Transl Med. 2013 May 6;11:112. doi: 10.1186/1479-5876-11-112.

8.

Anti-interleukin-5 (mepolizumab) therapy for hypereosinophilic syndromes.

Garrett JK, Jameson SC, Thomson B, Collins MH, Wagoner LE, Freese DK, Beck LA, Boyce JA, Filipovich AH, Villanueva JM, Sutton SA, Assa'ad AH, Rothenberg ME.

J Allergy Clin Immunol. 2004 Jan;113(1):115-9. Epub 2003 Dec 12.

PMID:
14699394
9.

The lymphoid variant of hypereosinophilic syndrome: study of 21 patients with CD3-CD4+ aberrant T-cell phenotype.

Lefèvre G, Copin MC, Staumont-Sallé D, Avenel-Audran M, Aubert H, Taieb A, Salles G, Maisonneuve H, Ghomari K, Ackerman F, Legrand F, Baruchel A, Launay D, Terriou L, Leclech C, Khouatra C, Morati-Hafsaoui C, Labalette M, Borie R, Cotton F, Gouellec NL, Morschhauser F, Trauet J, Roche-Lestienne C, Capron M, Hatron PY, Prin L, Kahn JE; French Eosinophil Network.

Medicine (Baltimore). 2014 Oct;93(17):255-66. doi: 10.1097/MD.0000000000000088.

10.

Mepolizumab in eosinophilic disorders.

Abonia JP, Putnam PE.

Expert Rev Clin Immunol. 2011 Jul;7(4):411-7. doi: 10.1586/eci.11.27. Review.

11.

Mepolizumab as a steroid-sparing treatment option in patients with Churg-Strauss syndrome.

Kim S, Marigowda G, Oren E, Israel E, Wechsler ME.

J Allergy Clin Immunol. 2010 Jun;125(6):1336-43. doi: 10.1016/j.jaci.2010.03.028.

PMID:
20513524
13.

Marked and persistent eosinophilia in the absence of clinical manifestations.

Chen YY, Khoury P, Ware JM, Holland-Thomas NC, Stoddard JL, Gurprasad S, Waldner AJ, Klion AD.

J Allergy Clin Immunol. 2014 Apr;133(4):1195-202. doi: 10.1016/j.jaci.2013.06.037. Epub 2013 Aug 26.

14.

The proportion of CD3- CD4+ T-cell population remained unaffected after corticosteroids treatment for lymphocytic variant hypereosinophilic syndrome (L-HES).

Helbig G, Wichary R, Razny M, Rodzaj M, Wozniczka K, Dziaczkowska-Suszek J, Kyrcz-Krzemien S.

Scand J Immunol. 2010 Oct;72(4):372-3. doi: 10.1111/j.1365-3083.2010.02436.x. No abstract available.

PMID:
20883323
15.

Monoclonal anti-interleukin-5 treatment suppresses eosinophil but not T-cell functions.

Büttner C, Lun A, Splettstoesser T, Kunkel G, Renz H.

Eur Respir J. 2003 May;21(5):799-803.

16.

Interleukin-5 is the predominant eosinophilopoietin produced by cloned T lymphocytes in hypereosinophilic syndrome.

Schrezenmeier H, Thomé SD, Tewald F, Fleischer B, Raghavachar A.

Exp Hematol. 1993 Feb;21(2):358-65.

PMID:
8425573
17.

Hypereosinophilic syndromes.

Roufosse FE, Goldman M, Cogan E.

Orphanet J Rare Dis. 2007 Sep 11;2:37. Review.

18.

Diagnostic and therapeutic management in patients with hypereosinophilic syndromes.

Helbig G, Kyrcz-Krzemień S.

Pol Arch Med Wewn. 2011 Jan-Feb;121(1-2):44-52. Review.

19.

Pharmacokinetics and pharmacodynamics of mepolizumab, an anti-interleukin-5 monoclonal antibody.

Smith DA, Minthorn EA, Beerahee M.

Clin Pharmacokinet. 2011 Apr;50(4):215-27. doi: 10.2165/11584340-000000000-00000. Review.

PMID:
21348536
20.

Anti-IL-5 (mepolizumab) therapy reduces eosinophil activation ex vivo and increases IL-5 and IL-5 receptor levels.

Stein ML, Villanueva JM, Buckmeier BK, Yamada Y, Filipovich AH, Assa'ad AH, Rothenberg ME.

J Allergy Clin Immunol. 2008 Jun;121(6):1473-83, 1483.e1-4. doi: 10.1016/j.jaci.2008.02.033. Epub 2008 Apr 14.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk